Cell/gene therapies targeting MAGE-A4 peptide
AssigneesInnovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
InventorsLei Xiao, Chengfei Pu, Zhiyuan Cao, Xiaogang Shen, Dongqi Chen, Beibei Jia, Le Tian
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for treating a subject having cancer associated with melanoma-associated antigen 4 (MAGE-A4) peptide. The disclosure includes the embodiments relate to a chimeric antigen receptor (CAR) that binds MAGE-A4 peptide, a polynucleotide encoding a CAR that binds the MAGE-A4 peptide, a modified cell comprising a CAR that binds the MAGE-A4 peptide, and a population of modified cells comprising a CAR that binds the MAGE-A4 peptide.
Claims20
A chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain comprises amino acid sequence SEQ ID NO:
- 10 or 13, and wherein the intracellular domain comprises a CD3 zeta signaling domain and a co-stimulatory signaling domain comprising an intracellular domain of CD28 or 4-1 BB.
Dependencies are inferred from the claim text.